ID | 60631 |
フルテキストURL | |
著者 |
Kano, Hirohisa
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Ichihara, Eiki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Kaken ID
publons
Harada, Daijiro
Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center
Inoue, Koji
Department of Respiratory Medicine, Ehime Prefectural Central Hospital
Kayatani, Hiroe
Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center
Hosokawa, Shinobu
Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital
Kishino, Daizo
Department of Respiratory Medicine, Himeji Red Cross Hospital
Watanabe, Kazuhiko
Department of Internal Medicine, Okayama Saiseikai General Hospital
Ochi, Nobuaki
Department of General Internal Medicine 4, Kawasaki Medical School
Oda, Naohiro
Department of Internal Medicine, Fukuyama City Hospital
Hara, Naofumi
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Ninomiya, Kiichiro
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Hotta, Katsuyuki
Center for Innovative Clinical Medicine, Okayama University Hospital
Kaken ID
publons
researchmap
Maeda, Yoshinobu
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kaken ID
researchmap
Kiura, Katsuyuki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
|
抄録 | Most clinical trials of non-small-cell lung cancer (NSCLC) exclude patients with poor ECOG performance status (PS). Thus, the efficacy of immune checkpoint inhibitors (ICIs) in patients with poor PS remains unclear. Herein, we used data from a retrospective cohort to assess the potential clinical benefits of ICIs in NSCLC patients with poor PS. Data from NSCLC patients who received ICI monotherapy at 9 institutions between December 2015 and May 2018 were retrospectively analyzed. After excluding 4 patients who lacked PS data, a total of 527 ICI-treated patients, including 79 patients with PS 2 or higher, were used for our analyses. The progression-free survival (PFS) and overall survival (OS) of patients with PS 2 or higher were significantly shorter compared with those of PS 0-1 patients (median PFS, 4.1 vs 2.0 months;P < .001 and median OS, 17.4 vs 4.0 months;P < .001). Among NSCLC patients with programmed cell death protein-ligand 1 (PD-L1) expression of 50% or higher who were treated with pembrolizumab as first-line therapy, the median PFS times of patients with PS 2 and 0-1 were 7.3 and 8.1 months, respectively. There was no significant difference in PFS between patients with PS 2 and 0-1 (P = .321). Although poor PS was significantly associated with worse outcomes in NSCLC patients treated with ICIs, pembrolizumab as a first-line treatment in NSCLC patients expressing high levels of PD-L1 could provide a clinical benefit, even in patients with PS 2.
|
キーワード | immune checkpoint inhibitor
non-small cell-lung cancer
PD-L1
pembrolizumab
poor performance status
|
発行日 | 2020-07-29
|
出版物タイトル |
Cancer Science
|
巻 | 111巻
|
号 | 10号
|
出版者 | Wiley
|
開始ページ | 3739
|
終了ページ | 3746
|
ISSN | 1347-9032
|
NCID | AA11808050
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2020 The Authors.
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1111/cas.14590
|
ライセンス | https://creativecommons.org/licenses/by-nc/4.0/
|